“We have long known that oxidative stress and inflammation are involved in making arteries unhealthy over time, but we didn’t know why arteries begin to get inflamed and stressed. Something is triggering this,” Seals said. “We now suspect that, with age, the gut microbiota begins producing toxic molecules, including TMAO, which get into the blood stream, cause inflammation and oxidative stress and damage tissue.”

As our collection of resident gut bacteria changes with age, it increasingly produces harmful metabolites that damage veins and blood vessels, driving disease, a new study suggests.

Last year, resTORbio announced the positive results of its phase 2b human trial, which targeted the aging immune system with an immune system-boosting drug. Now, the company has announced the news that its therapy is moving to a phase 3 study later this year after successful negotiation with the FDA.

Targeting the mTOR pathway of aging

ResTORbio is a biopharmaceutical company that is developing therapies that directly target the aging processes in order to prevent or cure age-related diseases. Its primary candidate drug is RTB101, which targets part of the mTOR pathway, one of the pathways involved in aging.

The skin is our first line of defense against invading pathogens, and scientists at UC San Francisco and the San Francisco Veterans Administration (VA) Health Care System believe that it may be a cause of inflammaging, the age-related chronic inflammation that encourages a number of age-related diseases to develop.

As we age, we generally experience a rise in this low-grade chronic inflammation, thus increasing our risk for developing a variety of age-related diseases. There are a number of proposed sources of inflammaging, including senescent cell accumulation, cell debris, immunosenescence, and increasing bacterial burden.

In a previous article, we talked about the potential role of bacterial burden in relation to the microbiota of the gut and the age-related failure of the gut membrane, which allows bacterial contamination to invade the body and increase bacterial burden and inflammation. The gut microbiota has been proposed to be an origin point of inflammaging, and researchers suggest that the skin could be another.